HK Stock Market Move | AIM VACCINE(06660) has surged over 7%. The mRNA herpes zoster vaccine has recently applied for clinical trials.

AIM VACCINE (06660) rose by more than 7%, reaching a 7.09% increase to 5.89 Hong Kong dollars, with a trading volume of 27.0458 million Hong Kong dollars as of the time of the report. In terms of news, AIM VACCINE announced yesterday that its mRNA herpes zoster vaccine has recently been submitted for clinical review to the Center for Drug Evaluation of the China Food and Drug Administration. In preclinical animal experiments, the results of the third-party testing unit showed that the group's mRNA herpes zoster vaccine had significantly higher levels of specific T-cell immunity, specific IgG antibody titers, and membrane antigen fluorescence antibody titers compared to commercially available recombinant subunit control vaccines. The group has established a comprehensive mRNA vaccine quality management system and a GMP-compliant commercial-scale production workshop. The mRNA technology platform has been validated by data from tens of thousands of human clinical trials of mRNA vaccine products. The group has established a complete process for the entire lifecycle of mRNA vaccine research and development, and can quickly achieve industrialization and commercialization of mRNA vaccine products after completing clinical trials.